AbCellera Biologics Inc.

2.31
-0.05 (-2.12%)
At close: Mar 28, 2025, 3:59 PM
2.30
-0.43%
After-hours: Mar 28, 2025, 06:19 PM EDT

Company Description

AbCellera Biologics Inc. develops antibody discovery platform.

Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs.

As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.

AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company.

The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc.
AbCellera Biologics Inc. logo
Country CA
IPO Date Dec 11, 2020
Industry Biotechnology
Sector Healthcare
Employees 596
CEO Dr. Carl L.G. Hansen Ph.D.

Contact Details

Address:
2215 Yukon Street
Vancouver, BC
CA
Website https://www.abcellera.com

Stock Details

Ticker Symbol ABCL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001703057
CUSIP Number 00288U106
ISIN Number CA00288U1066
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Carl L.G. Hansen Ph.D. Chief Executive Officer, President & Chairperson
Andrew Booth M.B.A. Chief Financial Officer
Dr. Veronique Lecault Ph.D. Chief Technology Officer & Director
Tryn T. Stimart Esq., J.D., M.Sc. Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer
Adam Clarke M.A.I.C.D., Ph.D. Senior Vice President of Discovery
Graham Craig M.Sc. Director of Corporate Development
Marcie Thiessen CPA, CGA Senior Director of Finance & Accounting
Murray McCutcheon Ph.D. Senior Vice President of Partnering
Neil Aubuchon B.A., M.B.A. Chief Commercial Officer
Tiffany Chiu B.Sc., Ph.D. Vice President of Communications

Latest SEC Filings

Date Type Title
Mar 11, 2025 4 Filing
Mar 10, 2025 4 Filing
Mar 07, 2025 4 Filing
Feb 27, 2025 S-3ASR Automatic shelf registration statement of securiti...
Feb 27, 2025 S-8 Filing
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 18, 2025 8-K Current Report
Jan 03, 2025 4 Filing
Jan 03, 2025 4 Filing